TY - JOUR
T1 - The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma
AU - Engert, A.
AU - Sausville, E. A.
AU - Vitetta, E.
PY - 1998
Y1 - 1998
N2 - Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.
AB - Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.
UR - http://www.scopus.com/inward/record.url?scp=0031838566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031838566&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-72153-3_2
DO - 10.1007/978-3-642-72153-3_2
M3 - Review article
C2 - 9670610
AN - SCOPUS:0031838566
VL - 234
SP - 13
EP - 33
JO - Ergebnisse der Hygiene, Bakteriologie, Immunitätsforschung und experimentellen Therapie
JF - Ergebnisse der Hygiene, Bakteriologie, Immunitätsforschung und experimentellen Therapie
SN - 0070-217X
ER -